Low AAT Levels in Patients With AATD Linked With Altered Lung Function Parameters
Pulmonary Carcinoid Tumorlets Found in Explanted Lungs After Transplantation
PiZZ AATD Shown to Be a Risk Factor for Hepatic Disease in Children
Lung Inflammation Observed in People With AATD Prior to Symptom Onset
Diagnostic Delay in AATD Linked With Worse Overall Survival and Transplant-Free Survival
An Interview With Scott Santarella, President and CEO of the Alpha-1 Foundation
Study Identifies Novel Genetic Mutations Contributing to the Development of AATD
No Association Between Pi*Z Heterozygosity and Liver Fibrosis in Patients With HCV
AATD PiZ Variant More Prevalent Among Patients With Bronchiectasis
New Study to Examine Whether Fazirsiran Can Reduce Liver Scarring in AATD
EARCO International Registry Provides Novel Information on Patients With AATD
Fazirsiran Shows Promise in Treating AATD-Associated Liver Disease
Latest Clinical Trials
AATD Screening Programs, Public Education, and Smoking Cessation
A combination of targeted screening programs and smoking cessation initiatives can turn the tide against severe AATD.
The Relationship Between Lung Disease in AATD and Psychiatric Illness
Studies reveal that manifestations of lung disease in AATD are associated with symptoms of depression and/or anxiety.
The Importance of Active Surveillance When Treating AATD
Active surveillance of important health parameters in AATD is important to ensure that quality of life is preserved as much as possible.
How I Calm Down Other People With AATD
The way I, a patient, talk with other people with alpha-1 antitrypsin deficiency (AATD) determines a lot of things.
This Patient With AATD Is Grateful to Live in the United States
I have come across people with alpha-1 antitrypsin deficiency (AATD) who tell me they’re getting denied treatment for this very real condition.
When Insurance Repeatedly Denies AATD Infusion Therapy
I have been waiting for insurance to approve augmentation therapy for my AATD for about 3 months.
A Book That Helps Me Deal With Life With AATD
One of the more difficult aspects of relationships is where I draw the line to allow or not allow unhealthy behavior.
Alpha-1 Foundation Strives to Accelerate Development of New AATD Treatments
Scott Santarella spoke with Rare Disease Advisor about his new leadership position at the Alpha-1 Foundation based in Miami, Florida.
Omidubicel Shows Promise as Replacement for Umbilical Cord Blood in Stem Cell Transplants
Gamida Cell is gearing up to begin sales of omidubicel from Israel to US hospitals for use in stem cell transplants, pending FDA approval of the therapy.
The Alliance for Regenerative Medicine Fights for Better Cell, Gene Therapies
The Alliance for Regenerative Medicine aims to help in the development of safe and effective regenerative therapies that can benefit rare disease patients.
Aytu BioPharma’s Healight Device Could Help Treat Rare Pulmonary Diseases
Aytu BioPharma has developed an endotracheal respiratory catheter which its CEO says has “tremendous potential” in IPF, PAH, and other respiratory diseases.
Rare Care Podcast
Israeli biopharma giant Kamada is banking that its inhaled AAT therapy will “revolutionize” the treatment of alpha-1 antitrypsin deficiency (AATD).
Mark Brantly, MD, scientific director of the Alpha-1 Foundation, is the vice-chair of research in the Department of Medicine at the University of Florida in Gainesville, and has spent most of his career researching a cure for alpha-1 antitrypsin deficiency (AATD).
Alpha-1 Meeting Coverage